{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T13:13:16Z","timestamp":1649077996198},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T00:00:00Z","timestamp":1229472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s11883-009-0006-x","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T18:46:43Z","timestamp":1229453203000},"page":"36-42","source":"Crossref","is-referenced-by-count":0,"title":["Should we treat all primary prevention patients with statins?"],"prefix":"10.1007","volume":"11","author":[{"given":"Robert","family":"Guthrie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,17]]},"reference":[{"key":"6_CR1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J. Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe JM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men high hypercholesterolemia. N Engl J Med 1995, 333:1301\u20131307.","journal-title":"N Engl J Med"},{"key":"6_CR2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","volume":"357","author":"I. Ford","year":"2007","unstructured":"Ford I, Murray H, Packard CJ, et al.: Long-term follow-up of the West of Scotland coronary Prevention Group. N Engl J Med 2007, 357:1477\u20131485.","journal-title":"N Engl J Med"},{"key":"6_CR3","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"J.R. Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (AFCAPS\/TexCAPS). JAMA 1998, 279:1615\u20131622.","journal-title":"JAMA"},{"key":"6_CR4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.101.5.477","volume":"101","author":"A.M. Gotto","year":"2000","unstructured":"Gotto AM, Whitney E, Stein EA, et al.: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force\/Texas coronary Atherosclerosis prevention study. Circulation 2000, 101:477\u2013495.","journal-title":"Circulation"},{"key":"6_CR5","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"P.S. Sever","year":"2003","unstructured":"Sever PS, Dahlof NR, Wedel H, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients how have average or lower-that-average cholesterol concentrations (ASCOT-LLA). Lancet 2003, 361:1149\u20131158.","journal-title":"Lancet"},{"key":"6_CR6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J. Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly patients as risk of vascular disease (PROSPER). Lancet 2002, 360:1623\u20131630.","journal-title":"Lancet"},{"key":"6_CR7","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0002-9149(99)00533-0","volume":"84","author":"J. Shepherd","year":"1999","unstructured":"Shepherd J, Blauw GJ, Murphy MB, et al.: The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 1999, 84:1192\u20131197.","journal-title":"Am J Cardiol"},{"key":"6_CR8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/CIRCULATIONAHA.106.671826","volume":"117","author":"K. Mizuno","year":"2008","unstructured":"Mizuno K, Nakaya N, Ohashi Y, et al.: Usefulness of pravastatin in primary prevention of cardiovascular events in women (MEGA). Circulation 2008, 117:494\u2013502.","journal-title":"Circulation"},{"key":"6_CR9","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","volume":"288","author":"ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Collaborative Research Group: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. JAMA 2002, 288:2998\u20133007.","journal-title":"JAMA"},{"key":"6_CR10","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1001\/jama.288.23.3042","volume":"288","author":"R.C. Pasternak","year":"2002","unstructured":"Pasternak RC: The ALLHAT Lipid Lowering Trial\u2014less is less. JAMA 2002, 288:3042\u20133044.","journal-title":"JAMA"},{"key":"6_CR11","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","volume":"108","author":"Ridker PM, for the JUPITER Study Group","year":"2003","unstructured":"Ridker PM, for the JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity c-reactive protein: rationale and design of the JUPITER Trial. Circulation 2003, 108:2292\u20132297.","journal-title":"Circulation"},{"key":"6_CR12","unstructured":"Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence of Benefit [press release]. London, UK: AstraZeneca; March 31, 2008."},{"key":"6_CR13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","volume":"251","author":"Lipid Research clinics program","year":"1984","unstructured":"Lipid Research clinics program: The Lipid Research clinics coronary primary prevention trial results (LRC-CPPT). JAMA 1984, 251:351\u2013364.","journal-title":"JAMA"},{"key":"6_CR14","first-page":"216","volume-title":"Contemporary Diagnosis and Management of Lipid Disorders","author":"A.M. Gotto","year":"2004","unstructured":"Gotto AM: Contemporary Diagnosis and Management of Lipid Disorders, edn 3. Newtown, PA: Handbooks in Health Care; 2004:216.","edition":"edn 3"},{"key":"6_CR15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","volume":"40","author":"Committee of Principal Investigators","year":"1978","unstructured":"Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978, 40:1069\u20131118.","journal-title":"Br Heart J"},{"key":"6_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","volume":"231","author":"Coronary Drug Project Research Group","year":"1975","unstructured":"Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360\u2013381.","journal-title":"JAMA"},{"key":"6_CR17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","volume":"317","author":"M.H. Frick","year":"1987","unstructured":"Frick MH, Elo O, Happa K, et al.: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987, 317:1237\u20131245.","journal-title":"N Engl J Med"},{"key":"6_CR18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jama.1988.03410050061031","volume":"260","author":"V. Manninen","year":"1988","unstructured":"Manninen V, Elo MO, Frick MH, et al.: Lipid alterations and decline in the incidenxce of coronary heart disease in the Helsinki Heart Study [abstract]. JAMA 1988, 260:641.","journal-title":"JAMA"},{"key":"6_CR19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archinte.166.7.743","volume":"166","author":"L. Tenkanen","year":"2006","unstructured":"Tenkanen L, Manttari M, Kovanen PT, et al.: Gemfibrozil in the treatment of dyslipidemia. Arch Intern Med 2006, 166:743\u2013748.","journal-title":"Arch Intern Med"},{"key":"6_CR20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","volume":"341","author":"H.B. Rubins","year":"1999","unstructured":"Rubins HB, Ropins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary hears disease in men with low levels of high-density lipoprotein cholesterol (VA-HIT). N Engl J Med 1999, 341:410\u2013418.","journal-title":"N Engl J Med"},{"key":"6_CR21","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","volume":"285","author":"S.J. Robins","year":"2001","unstructured":"Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events (VA-HIT). JAMA 2001, 285:1585\u20131591.","journal-title":"JAMA"},{"key":"6_CR22","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"FIELD Study Investigators","year":"2005","unstructured":"FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study). Lancet 2005, 366:1849\u20131861.","journal-title":"Lancet"},{"key":"6_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","volume":"102","author":"BIP Study Group","year":"2000","unstructured":"BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary heart disease. Circulation 2000, 102:21\u201336.","journal-title":"Circulation"},{"key":"6_CR24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","volume":"8","author":"P.L. Canner","year":"1986","unstructured":"Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug project patients: Long-Term benefits with niacin. J Am Coll Cardiol 1986, 8:1245\u20131255.","journal-title":"J Am Coll Cardiol"},{"key":"6_CR25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9149(00)01230-3","volume":"86","author":"H.R. Arntz","year":"2000","unstructured":"Arntz HR, Agrawal R, Wunderlich W, et al.: Beneficial effects of pravastatin (+\/- colestyramine\/niacin) initiated immediately after a coronary event (L-CAD Study). Am J Cardiol 2000, 86:1293\u20131298.","journal-title":"Am J Cardiol"},{"key":"6_CR26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0735-1097(94)90635-1","volume":"23","author":"B.F. Stewart","year":"1994","unstructured":"Stewart BF, Brown BG, Zhao XQ, et al.: Benefits of lipidlowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 1994, 23:899\u2013906.","journal-title":"J Am Coll Cardiol"},{"key":"6_CR27","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","volume":"257","author":"D.H. Blankenhorn","year":"1987","unstructured":"Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233\u20133240.","journal-title":"JAMA"},{"key":"6_CR28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","volume":"223","author":"L.A. Carlson","year":"1988","unstructured":"Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405\u2013418.","journal-title":"Acta Med Scand"},{"key":"6_CR29","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","volume":"284","author":"M.B. Elam","year":"2000","unstructured":"Elam MB, Hunnihake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease (ADMIT). JAMA 2000, 284:1263\u20131270.","journal-title":"JAMA"},{"key":"6_CR30","unstructured":"Zetia [package insert]. North Wales, PA: Merck-Schering-Plough Pharmaceuticals; 2007."},{"key":"6_CR31","unstructured":"Merck\/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial [press release]. North Wales, PA: Merck\/Schering-Plough Pharmaceuticals; January 14, 2008."},{"key":"6_CR32","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"P.J. Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109\u20132122.","journal-title":"N Engl J Med"},{"key":"6_CR33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.0889-7204.2006.05616.x","volume":"Summer","author":"R.M. Guthrie","year":"2006","unstructured":"Guthrie RM: How safe is aggressive statin therapy? Prog Cardiovasc Nurs 2006, Summer:140\u2013145.","journal-title":"Prog Cardiovasc Nurs"},{"key":"6_CR34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jacl.2008.04.023","volume":"2","author":"M.H. Davidson","year":"2008","unstructured":"Davidson MH, Carlson DM, Guthrie RM, et al.: ABT-335 in combination with rosuvastatin improves multiple lipid ratios in patients with mixed dyslipidemia. J Clin Lipidol 2008, 2:211\u2013212.","journal-title":"J Clin Lipidol"},{"key":"6_CR35","first-page":"56i","volume":"99","author":"H.N. Gisnberg","year":"2007","unstructured":"Gisnberg HN, Bonds DE, Lovato LC, et al.: Evolution of the lipid trial protocol of the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol 2007, 99:56i\u201367i.","journal-title":"Am J Cardiol"},{"key":"6_CR36","unstructured":"Niacin plus statin to prevent cardiovascular events (AIM-HIGH). Available at: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00120289 . Accessed on September 2, 2008."},{"key":"6_CR37","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMcp070061","volume":"357","author":"J.D. Brunzell","year":"2007","unstructured":"Brunzell JD: Hypertryglyceridemia. N Engl J Med 2007, 357:1009\u20131017.","journal-title":"N Engl J Med"},{"key":"6_CR38","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N. Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, et al.: Triglycerides and the risk of heart disease. Circulation 2007, 115:450\u2013458.","journal-title":"Circulation"},{"key":"6_CR39","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","volume":"97","author":"T.R. Pedersen","year":"1998","unstructured":"Pedersen TR, Olsson AG, Faergeman O, et al.: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453\u20131460.","journal-title":"Circulation"},{"key":"6_CR40","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","volume":"97","author":"West of Scotland Coronary Prevention group","year":"1998","unstructured":"West of Scotland Coronary Prevention group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440\u20131445.","journal-title":"Circulation"},{"key":"6_CR41","unstructured":"IDEAL: Lowering triglycerides in stable statin-treated CHD patients does not provide benefit [press release]. Heart wire\/Cardiometabolic Risk; May 2, 2008."},{"key":"6_CR42","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M. Miller","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, et al.; for the PROVE IT-TIMI 22 Investigators: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724\u2013730.","journal-title":"J Am Coll Cardiol"},{"key":"6_CR43","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","volume":"105","author":"R. Marchioli","year":"2002","unstructured":"Marchioli R, Barzi F, Bomba E, et al.; for the GISSI-Prevenzione Investigators: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Circulation 2002, 105:1897\u20131909.","journal-title":"Circulation"},{"key":"6_CR44","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.295.22.2613","volume":"295","author":"I.A. Brouwer","year":"2006","unstructured":"Brouwer IA, Zock PL, Camm J, et al.; for the SOFA Group: Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators. JAMA 2006, 295:2613\u20132619.","journal-title":"JAMA"},{"key":"6_CR45","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1001\/jama.293.23.2884","volume":"293","author":"M.H. Raitt","year":"2005","unstructured":"Raitt MH, Connor WE, Morris C, et al.: Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators. JAMA 2005, 293:2884\u20132891.","journal-title":"JAMA"},{"key":"6_CR46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"119","author":"S.M. Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz NB, for the coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 119:227\u2013239.","journal-title":"Circulation"},{"key":"6_CR47","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"S.E. Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared witah moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004, 291:1071\u20131080.","journal-title":"JAMA"},{"key":"6_CR48","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","volume":"297","author":"J.R. Crouse","year":"2007","unstructured":"Crouse JR, Raichlen JS, Riley WA, et al.; for the METEOR Study Group: Effect of rosuvastatin in progression of carotid intime-media thickness in lo0w-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297:1344\u20131353.","journal-title":"JAMA"},{"key":"6_CR49","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/14740338.6.5.573","volume":"6","author":"R.M. Guthrie","year":"2007","unstructured":"Guthrie RM, Martin DR: The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf 2007, 6:573\u2013581.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-009-0006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-009-0006-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-009-0006-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:35:34Z","timestamp":1559432134000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-009-0006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,17]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s11883-009-0006-x","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,17]]}}}